With more than 500 patients now randomized and enrollment closing roughly four months ahead of schedule, 4D Molecular Therapeutics has completed enrollment in 4FRONT-2, the global Phase 3 trial of its gene therapy candidate 4D-150 in wet age-related macular degeneration. That pace matters more than it might appear. Clinical sites routinely undershoot enrollment targets in retinal trials because patients are elderly, often undertreated, and geographically dispersed. Over-enrolling a pivotal study in this population is a genuine signal of investigator confidence, not a paperwork footnote.
The design of 4FRONT-2 is deliberately conservative in the right places and ambitious in others. The primary endpoint asks only for non-inferiority in best corrected visual acuity change from baseline at 52 weeks versus aflibercept 2 mg dosed every eight weeks, a bar that protects patients while giving the gene therapy room to prove itself on its real differentiator. The key secondary endpoint, comparing the actual number of aflibercept injections received in each arm over 52 weeks, is where the commercial argument lives. Wet AMD currently demands lifelong intravitreal dosing; approved agents including faricimab (Vabysmo) and brolucizumab (Beovu) have extended intervals but have not escaped that paradigm. A single injection designed to deliver sustained anti-VEGF expression for potentially multiple years is a structurally different proposition, and the burden-reduction endpoint will either validate that framing in 2027 or expose it.
4DMT now has two pivotal readouts converging within the same calendar year. 4FRONT-1, a North American trial of 523 treatment-naive patients with an otherwise identical design, completed randomization in March 2026 and is expected to deliver 52-week topline results in H1 2027. 4FRONT-2 topline data follows in H2 2027. The geographic breadth of 4FRONT-2, which enrolled both treatment-naive and recently treatment-experienced patients across international sites, gives the dataset better generalizability and should support regulatory submissions in multiple markets simultaneously. A Phase 3 initiation in diabetic macular edema is also planned for Q3 2026, meaning 4DMT is attempting to build a multi-indication gene therapy franchise on a single vector platform in real time.
The single number to watch heading into 2027 is the injection count in the 4D-150 arm of 4FRONT-2 over 52 weeks. If supplemental aflibercept use is meaningfully lower than in the comparator arm while BCVA holds, the durability story survives Phase 3 scrutiny. If the supplemental injection rate converges, the differentiation case collapses regardless of what the primary endpoint shows.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
